Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Avatar Builder  |  Contact Info  |  Update Email  |  Update Password  |  Leaderboards  |  Manage Favourite  |  Reputation  |  Reputation History  |  Subscriptions  |  Payment Info  |  Invoices  |  Favourites

Bullboard Post History

by Eoganacht

V.TLT

RE:The Sesen comparison

"In the first cohort of 82 evaluable patients who completed the...

June 2, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:88% demonstrate that CR at 180 days, 69% at 270 days

Thanks 99942Apophis. I think that 13.2% CR at 450 days represents 2...

May 31, 2022

V.TLT

RE:RE:RE:RE:RE:RE:RE:RE:RE:88% demonstrate that CR at 180 days, 69% at 270 days

Good post CancerSlayer. Here's a question I'm not sure anyone has an...

May 31, 2022

V.TLT

RE:RE:When push comes to shove...

Makes sense ScienceFirst. And as far as the chances of getting FDA approval...

May 31, 2022

V.TLT

When push comes to shove...

... there's very little doubt Theralase will be able to demonstrate ...

May 31, 2022

V.TLT

First quarter financials

will probably be released some time in the next 8 hours.

May 30, 2022

V.TLT

RE:RE:RE:RE:RE:RE:This constant selling...........

But Hutchmed, Li Ka-shing's cancer drug company might... Hutchmed was...

May 27, 2022

V.TLT

Theralase Hiring - Ad Posted Today

Electronics Engineering Technologist Toronto, ON $60,000–$70,000 a year ...

May 26, 2022

V.TLT

RE:RE:Just Phase 2 results - 35 patients

Right! Rumpl3StiltSkin wrote: And this is still including the non-optimized...

May 25, 2022

V.TLT

RE:RE:Just Phase 2 results - 35 patients

Hi Pandora - I think the majority of the NR patients are the first 12...

May 25, 2022

V.TLT

Just Phase 2 results - 35 patients

I rejigged the latest data (April 29) a little bit. I'm not sure if an...

May 25, 2022

V.TLT

RE:Virus destruction

I believe there's still a long way to go. A phase 1 trial won't...

May 20, 2022

V.TLT

RE:RE:RE:RE:RE:Roger exercised warrants

https://m.canadianinsider.com/company?ticker=TLT May 14, 2022 (filed on...

May 17, 2022

V.TLT

RE:RE:RE:Preliminary Results from BCG-Unresponsive NMIBC Treatment

Hi CancerSlayer, I just reread Dr. Li's comments and I think you're...

May 17, 2022

V.TLT

RE:RE:Preliminary Results from BCG-Unresponsive NMIBC Treatment

Right. 20 out of 22 CR at 3 months is 91% CR. 15 out of 22 CR at 6 months is...

May 17, 2022

V.TLT

RE:RE:Preliminary Results from BCG-Unresponsive NMIBC Treatment

No, the combo had a 6% higher CR rate at 12 months than the standalone...

May 16, 2022

V.TLT

Preliminary Results from BCG-Unresponsive NMIBC Treatment

Preliminary results for a phase 2 trial of CG0070 used in conjunction with...

May 16, 2022

V.TLT

Final clinical results of N-803 BCG Unresponsive NMIBC Trial

 were presented at the AUA2022 yesterday, Friday, May 13. We already...

May 14, 2022

V.TLT

Pivotal Phase 2 Trial for NSCLC ?

I think one of the reasons Theralase may have chosen NSCLC as their next...

May 10, 2022

V.TLT

Hutchmed Hit Hard by Cancer Drug Approval Failure in US

Li Ka-shing’s HutchMed plunges in US$500 million stock rout as cancer drug...

May 10, 2022

Prev ... 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 ... Next

Featured Company

Grid Battery Metals Inc.

Grid Battery Metals Inc. V.CELL

Grid Battery Metals Inc. is a Canada-based exploration company. The Company focuses on exploration for high-value battery ... view more »